We use cookies to improve your experience. By your continued use of this site you accept such use.
EVA Pharma

  • Multimedia content

  • Images (3)
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources (FR)
    • EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources (AR)
  • All (3)
Source: EVA Pharma |

EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High Human Immunodeficiency Virus (HIV) Incidence and Limited Resources

Under this royalty-free voluntary licensing agreement EVA Pharma will manufacture and supply Lenacapavir active pharmaceutical ingredient and finished pharmaceutical product

EVA Pharma (www.EVAPharma.com) announced today a non-exclusive, royalty-free voluntary licensing agreement signed with Gilead (https://apo-opa.co/4dB3Nwx), allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility…

EVA Pharma

  • Multimedia content

  • Images (3)
    • Biologics Facility Tour
    • EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly
    • EVA Biologics Group Photo
  • All (3)
Source: EVA Pharma |

EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly

The new facility has production capacity of 90 million vials and 50 million cartridges of high-quality insulin to meet the needs of at least one million people annually in Africa, as part of collaboration with Lilly

EVA Pharma (https://www.EVAPharma.com) is celebrating the completion of its new biologics’ facility in Cairo, which is set to start producing high-quality insulin next month as part of an ongoing collaboration with Eli Lilly and Company to expand sustainable access to the essential medical product. In a first for both companies,…

EVA Pharma

  • Multimedia content

  • Images (5)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (1)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (2)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (3)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (4)
    • Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (5)
  • All (5)
Source: EVA Pharma |

Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries

Eli Lilly and Company (NYSE: LLY) and EVA Pharma (http://www.EVAPharma.com/) announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are…

EVA Pharma

  • Multimedia content

  • Videos (1)
    • Remdesivir from our hands to yours - Manufacturing Process
  • Images (5)
    • Supporting India amid COVID-19 surge (1)
    • Supporting India amid COVID-19 surge (2)
    • Supporting India amid COVID-19 surge (3)
    • Supporting India amid COVID-19 surge (4)
    • Supporting India amid COVID-19 surge (5)
  • All (6)
Source: EVA Pharma |

Supporting India amid COVID-19 surge

EVA Pharma signed a contract with the Indian government to export 300,000 vials of Remdesivir

EVA Pharma’s (www.EVAPharma.com) timely shipments of Remdesivir reached India during a major wave of coronavirus cases. When India experienced an unexpected COVID-19 surge this spring, the rapid increase in cases put pressure on the local pharmaceutical industry to supply the medicines needed. In April, EVA Pharma signed a contract with…